Table 1. Baseline characteristics of entire cohort and dichotomized by age groups with univariate analysis.
| |
Entire cohort (N=439) |
Young cohort aged <70 years (n=261) |
Elderly cohort aged ⩾70 years (n=178) |
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variables | n (%) | Median OS (months) | P-value (log-rank) | n (%) | Median OS (months) | P-value (log-rank) | n (%) | Median OS (months) | P-value (log-rank) | P-valuea |
|
Mean age, years |
65.9 |
|
|
59.57 |
|
|
75.2 |
|
|
0.085 |
| Median |
67 |
|
|
|
|
|
|
|
|
|
| Range |
28–87 |
|
|
|
|
|
|
|
|
|
|
Gender |
|
|
|
|
|
|
|
|
|
0.006 |
| Male |
230 (52.4) |
18.5 |
0.795 |
151 (57.9) |
19.6 |
0.470 |
79 (44.4) |
16.5 |
0.431 |
|
| Female |
209 (47.6) |
17.8 |
|
110 (42.1) |
22.1 |
|
99 (55.6) |
15.6 |
|
|
|
Stage |
|
|
|
|
|
|
|
|
|
0.008 |
| 1A |
10 (2.3) |
25.7 |
0.139 |
7 (2.7) |
24.8 |
0.884 |
3 (1.7) |
40.5 |
0.037 |
|
| 1B |
21 (4.9) |
|
|
18 (7.0) |
|
|
3 (1.7) |
|
|
|
| 2A |
114 (26.4) |
17.6 |
|
55 (21.4) |
19.6 |
|
59 (33.7) |
15.7 |
|
|
| 2B |
287 (66.4) |
|
|
177 (68.9) |
|
|
110 (62.9) |
|
|
|
|
Differentiation |
|
|
|
|
|
|
|
|
|
0.457 |
| Well |
33 (8.9) |
26.2 |
0.373 |
16 (7.4) |
26.2 |
0.576 |
17 (10.9) |
21.8 |
0.425 |
|
| Moderate |
238 (63.8) |
17.5 |
|
139 (64.1) |
20.2 |
|
99 (63.5) |
13.3 |
|
|
| Poor |
102 (27.3) |
18.1 |
|
62 (28.6) |
19.6 |
|
40 (25.6) |
16.0 |
|
|
|
Tumour location |
|
|
|
|
|
|
|
|
|
0.299 |
| Head |
369 (86.0) |
18.5 |
0.021 |
223 (87.5) |
21.3 |
0.642 |
146 (83.9) |
16.9 |
0.005 |
|
| Body/tail |
60 (14.0) |
12.8 |
|
32 (12.5) |
19.3 |
|
28 (16.1) |
8.9 |
|
|
|
Tumour size (mm) |
|
|
|
|
|
|
|
|
|
0.827 |
| ⩽20 |
103 (23.6) |
25.0 |
0.001 |
62 (23.9) |
27.5 |
0.049 |
41 (23.0) |
24.4 |
0.005 |
|
| >20 |
334 (76.4) |
16.6 |
|
197 (76.1) |
19.4 |
|
137 (77.0) |
12.8 |
|
|
|
Margins (0 mm) |
|
|
|
|
|
|
|
|
|
0.345 |
| Clear |
272 (62.0) |
22.1 |
<0.0001 |
157 (60.2) |
23.4 |
<0.0001 |
115 (64.6) |
18.0 |
<0.0001 |
|
| Involved |
167 (38.0) |
13.5 |
|
104 (39.8) |
16.0 |
|
63 (35.4) |
11.0 |
|
|
|
Lymph nodes |
|
|
|
|
|
|
|
|
|
0.121 |
| Negative |
144 (33.3) |
19.7 |
0.025 |
78 (30.4) |
21.5 |
0.082 |
66 (37.5) |
18.0 |
0.122 |
|
| Positive |
289 (66.7) |
17.2 |
|
179 (69.6) |
19.3 |
|
110 (62.5) |
13.1 |
|
|
|
Perineural invasion |
|
|
|
|
|
|
|
|
|
0.280 |
| Negative |
102 (23.6) |
25.4 |
0.010 |
56 (21.8) |
27.5 |
0.113 |
46 (26.3) |
20.9 |
0.022 |
|
| Positive |
330 (76.4) |
17.2 |
|
201 (78.2) |
19.5 |
|
129 (73.7) |
13.3 |
|
|
|
Vascular invasion |
|
|
|
|
|
|
|
|
|
0.012 |
| Negative |
224 (52.1) |
20.5 |
0.017 |
120 (47.1) |
20.5 |
0.845 |
104 (59.4) |
19.3 |
<0.0001 |
|
| Positive |
206 (47.9) |
16.4 |
|
135 (52.9) |
21.5 |
|
71 (40.6) |
12.0 |
|
|
|
Radiotherapy |
|
|
|
|
|
|
|
|
|
0.040 |
| No adjuvant |
416 (95.2) |
18.1 |
0.752 |
243 (93.5) |
19.7 |
0.830 |
173 (97.7) |
15.9 |
0.452 |
|
| Adjuvant |
21 (4.8) |
18.6 |
|
17 (6.5) |
21.5 |
|
4 (2.3) |
10.7 |
|
|
|
Adjuvant chemotherapy |
|
|
|
|
|
|
|
|
|
<0.0001 |
| Adjuvant |
187 (42.7) |
22.1 |
<0.0001 |
134 (51.5) |
22.5 |
0.085 |
53 (29.8) |
21.8 |
0.003 |
|
| No adjuvant |
251 (57.3) |
15.8 |
|
126 (48.5) |
17.5 |
|
125 (70.2) |
13.1 |
|
|
|
Palliative chemotherapy |
|
|
|
|
|
|
|
|
|
0.002 |
| No palliative therapy |
314 (71.7) |
16.5 |
0.74 |
188 (67.9) |
18.5 |
0.266 |
126 (78.3) |
13.3 |
0.582 |
|
| Palliative therapy |
124 (28.3) |
21.3 |
|
89 (32.1) |
21.5 |
|
35 (21.7) |
21.1 |
|
|
|
Outcome |
|
|
|
|
|
|
|
|
|
|
| Pancreatic cancer death |
318 (72.4) |
|
|
182 (69.7) |
|
|
136 (76.4) |
|
|
0.124 |
| Death – other causes |
29 (6.6) |
|
|
16 (6.1) |
|
|
13 (7.3) |
|
|
|
| Alive |
92 (21.0) |
|
|
63 (24.1) |
|
|
29 (16.3) |
|
|
|
| Median overall survival (months) | 18.1 | 20.2 | 15.8 | 0.085 | ||||||
Abbreviation: OS=overall survival.
a
Comparison of variables between <70 cohort and ⩾70 cohort.